<DOC>
	<DOCNO>NCT02087007</DOCNO>
	<brief_summary>This study conduct accordance local regulation New Drug Application . Overall duration trial 3 year approval KFDA . Each subject participate around 7 week , include 2 week Amlodipine run-in period , 4 week double blind period 1 week safety follow period</brief_summary>
	<brief_title>A Therapeutic Confirmatory Study Evaluate Efficacy Safety Cilostazol Subjects With Vasospastic Angina</brief_title>
	<detailed_description>A Multicenter , Randomized , Double-Blind , Placebo-controlled , Parallel group , Therapeutic confirmatory Study . The subject least one episode chest pain weekly least two episode chest pain last week despite Amlodipine 5mg qd take 2 week treatment Pletaal ( Cilostazol ) Placebo 4 week . Pletaal ( Cilostazol ) take 100mg oral tablet bid 2 week dose Pletaal ( Cilostazol ) 50mg oral tablet bid 2 week . Placebo Pletaal ( Cilostazol ) use control medication .</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina Pectoris , Variant</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>Subjects must meet follow inclusion criterion eligible enrollment study : 1 . Male female 20 age 20 age 80 . 2 . Patients show angina attack even rest screening , diagnose vasospastic angina within previous 3 month meet least one 3 definition , accompany insignificant ( stenosis rate &lt; 50 % ) coronary artery disease document coronary angiography within last 3 month [ temporary antispastic agent ( monotherapies combination Verapamil Nitroglycerin , anticoagulant ) coronary angiography allow ] Chest pain accompany least 2 temporary , closely locate ST elevation depression 0.1mV great absence ergonovine provoke coronary angiography . Positive Intracoronary ( IC ) Intravenous ( IV ) Ergonovine provocation test ; ischemic ECG change accompany chest pain spasm reduce coronary diameter 90 % ( least 2 temporary , closely locate ST elevation depression 0.1mV great 12lead ECG ) 3 . Patients report least 1 episode chest pain week amlodipine runin period least 2 episode final week . 4 . Women menopausal sterile least 1 year , woman childbearing potential agree practice contraceptive measure throughout clinical trial ( e.g. , hormonal contraceptive , intrauterine device , condom + spermicidal agent , diaphragm + spermicidal agent , partner 's infertility ) 5 . Subjects sign write agreement indicate give full explanation clinical trial willing participate clinical trial . Subjects present follow include study : 1 . Subjects use Cilostazol within 3 month screen visit 2 . Subjects use antiplatelet drug , include Aspirin , Clopidogrel , Ticlopidine Sarpogrelate , PDE3 inhibitor class Cilostazol , Amrinone , Milrinone Enoximone , initiation amlodipine runin period 3 . Subjects use oral anticoagulant , warfarin , within 1 month prior screen visit 4 . Subjects use follow drug within 1 week prior screen visit CCBs apart amlodipine Betablockers alphablockers Oral nitrate , exclude nitroglycerin sublingual tablet , Nicorandil Vitamin E preparation Estrogens 5 . History myocardial infarction myocardial infarction mediate vasospastic angina time screen 6 . History lifethreatening vasospastic event ( e.g. , ventricular tachycardia , atrial fibrillation syncope ) 7 . History stroke , intracranial hemorrhage transient ischemic attack ( TIA ) 8 . Hemorrhage ( hemophilia , capillary fragility , upper gastrointestinal bleeding , urinary tract bleeding , hemoptysis , vitreous hemorrhage , etc . ) predisposition ( active peptic ulcer , hemorrhage suspect Cilostazol administration surgical wound within last 3 month , proliferative diabetic retinopathy ) 9 . History hypersensitivity ingredient Cilostazol , amlodipine , dihydropyridines nitroglycerine , nitrate 10 . Severe aortic stenosis 11 . History shock 12 . Hypotension systolic pressure 90mmHg screen 13 . Severe anemia hemoglobin 6.5g/dl screen 14 . History glaucoma 15 . ST change abnormality interpretable ECG screen 16 . Congestive heart failure leave ventricular ejection fraction &lt; 40 % echocardiography screening within last 3 month 17 . Atrial fibrillation beyond moderate valvular heart disease 18 . Left main coronary spasm suspect confirmed coronary angiography ergonovine provoke coronary angiography 19 . History coronary artery bypass graft ( CABG ) percutaneous coronary intervention ( PCI ) 20 . Heart rate &gt; 100 bpm screen via vital sign : tachycardia 21 . Uncontrolled hypertension systolic pressure ≥ 160 mmHg diastolic pressure ≥ 100 mmHg screen 22 . Creatinine level ≥ 1.5 mg/dL screen 23 . AST ALT &gt; x3 ULN ( Upper Limit Normal ) screen 24 . Platelet count &lt; 100,000mm3 screen 25 . QT prolongation QTcB &gt; 450 msec male QTcB &gt; 470 msec female subject screen 26 . Women childbearing potential positive pregnancy test screen 27 . Women agree practice contraceptive measure , pregnant lactate woman 28 . Drug compliance le 80 % 2week amlodipine runin period 29 . Subjects otherwise judge investigator inappropriate inclusion trial 30 . Subjects use another investigational product within 2 month prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Treatment vasospastic angina</keyword>
</DOC>